The long-term objective of the Pharmacology Shared Resource is to provide critical pharmacologic support, services, and expertise for Cancer Center investigators engaged in the development and evaluation of anticancer agents.
The specific aims of the Shared Resource are to provide the necessary services and expertise for: 1) the conduct of clinical pharmacokinetic studies performed through the vigorous NCI-funded Phase I and Phase II clinical trials programs in the Cancer Center, 2) for the conduct of pharmacogenetic studies performed in conjunction with appropriate early clinical trials and 3) for the conduct of preclinical pharmacology studies in support of Cancer Center investigator research. To accomplish these aims, the Shared Resource has state of the art capabilities and expertise for the sensitive and specific analysis of drugs and their metabolites in biological specimens, for structure elucidation and pharmacologic characterization of drug metabolites, for the conduct of clinical and preclinical pharmacokinetic studies using those assay methodologies, for the detailed analysis of pharmacokinetic data and for the conduct of pharmacogenetic studies using validated assays for determination of allelic variants of genes related to drug response. In addition. Shared Resource key personnel consult with Cancer Center investigators in the design of studies and the analysis and interpretation of pharmacologic data obtained in those studies. The services and expertise of this Shared Resource are available only to Cancer Center members and are prioritized based on funding source, nature of the studies (clinical or preclinical investigations), scientific needs of the investigator and priorities within the Cancer Center. The Director is responsible for overall selection, prioritization and oversight of activity within the Shared Resource. Conduct of specific experiments is assigned to laboratory personnel based on the nature of the proposed laboratory studies. The Shared Resource provides the mechanism to conduct all pharmacologic studies in one integrated environment with substantial scientific and economic efficiencies. During the current funding period, the Shared Resource has contributed to over 45 clinical pharmacology protocol-based studies in conjunction with Phase I and Phase II clinical trials encompassing pharmacokinetic and pharmacogenetic elements. The Shared Resource also provided preclinical pharmacologic support for 14 Cancer Center investigator-initiated laboratory projects either for grant-funded studies or in preparation for grant submissions.
|Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33|
|Bogenberger, James M; Delman, Devora; Hansen, Nanna et al. (2015) Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56:226-9|
|Sami, Sarmed S; Ragunath, Krish; Iyer, Prasad G (2015) Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 13:623-34|
|Fackler, Mary Jo; Lopez Bujanda, Zoila; Umbricht, Christopher et al. (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-70|
|Porrata, Luis F; Ristow, Kay M; Habermann, Thomas M et al. (2014) Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 55:2728-38|
|Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43|
|Espejo, Rosario; Jeng, Yowjiun; Paulucci-Holthauzen, Adriana et al. (2014) PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity. J Cell Sci 127:497-508|
|Banck, Michaela S; Beutler, Andreas S (2014) Advances in small bowel neuroendocrine neoplasia. Curr Opin Gastroenterol 30:163-7|
|Boland, Jennifer M; Wampfler, Jason A; Jang, Jin S et al. (2014) Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol 38:1681-8|
|Imperiale, Thomas F; Ransohoff, David F; Itzkowitz, Steven H et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287-97|
Showing the most recent 10 out of 340 publications